SOURCE: Stock Market Alerts

August 19, 2009 09:38 ET

Morning Watch for Wednesday: Sunwin International Neutraceuticals - August 19, 2009

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Stock Market Alerts LLC.

MIAMI, FL--(Marketwire - August 19, 2009) - Stock Market Alerts' performance stock list includes: Sunwin International Neutraceuticals, Inc. (OTCBB: SUWN), Bristol-Myers Squibb Company (NYSE: BMY), Johnson & Johnson (NYSE: JNJ) and Medicis (NYSE: MRX).

Sunwin International Neutraceuticals, Inc. (OTCBB: SUWN) recently reported its financial results for the fiscal year 2009, which included record sales of stevioside that reached $14.5 million for the full fiscal year of 2009, an increase of 12.4% over the $12.9 million recorded in fiscal 2008. Now the company, a leader in the production and distribution of Chinese herbs, veterinary medicines and one of the world's leading producers of all natural, zero calorie stevia in China, has just issued additional news.

This morning, Sunwin International issued a press released announcing that it will present at the Rodman & Renshaw Annual Global Investment Conference taking place at the New York Palace Hotel September 9-11 as part of the Asia Track program on September 10th at 8:45 AM.

Sunwin's Chief Executive Officer, Dongdong Lin commented, "We are excited to be invited to the Rodman conference and look forward to presenting the exciting future of our company. Despite the global economic downturn, we have sustained our profitability and positioned the company for future growth. We intend to look to participate in additional conferences and meetings throughout the fall in order to increase the company's exposure to the investment community."

On July 30th, 2009, the company reported it's financial results for the fiscal year ended April 30, 2009. Sales of stevioside reached a record $14.5 million for the full fiscal year of 2009, an increase of 12.4% over the $12.9 million recorded in fiscal 2008. The global demand for stevioside continues to increase as regulatory authorities in the United States have approved the use of highly purified grades in the food and beverage industry. The strong performance in Sunwin's Stevioside Segment was more than offset by weakness in its Chinese and Veterinary Medicines Segment which was negatively impacted due to the global economic downturn, decreased breeding and farming production due to the swine flu pandemic and currency exchange rate fluctuations. As a result, for the full year of 2009 Sunwin International generated revenue of $22.21 million as compared to revenue of $22.93 million for the same period of 2008.

Cost of goods sold for the full fiscal year of 2009 increased slightly to $17.13 million, up approximately $280,000 as compared to fiscal 2008 resulting in gross margins decreasing to 23% as compared to 27% in fiscal 2008. The decrease in margins was largely attributable to lower production efficiency in its Chinese and Veterinary Medicine Segment due to soft demand.

For the fiscal year end April 30, 2009 net income was approximately $500,000 as compared to approximately $2,500 in fiscal 2008. This increase is attributable to a 25% reduction of selling, general and administrative expenses. This decrease in expenses was largely the result of a $788,277 decline in consulting expenses.

The stock closed yesterday at around Nineteen cents a share a share.

For an in-depth profile of Sunwin International Neutraceuticals, visit http://wallstreetenews.com/view-company-profiles.php?profile=SUWN_072909.

Bristol-Myers Squibb Company (NYSE: BMY) up 0.4% on 9.5 million shares traded. Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to extend and enhance human life.

Johnson & Johnson (NYSE: JNJ) down 0.03% on 8.8 million shares traded. Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

Medicis (NYSE: MRX) up 6.4% on 5.6 million shares traded. Medicis is the leading independent specialty pharmaceutical company in the United States focusing primarily on the treatment of dermatological and aesthetic conditions.

This advertisement is provided by Wall Street Enews, a division of Stock Market Alerts LLC, an electronic broadcaster and publisher of this release, and hereafter referred to as "the company." The company also maintains a contractual, working relationship with Wall Street Capital Funding LLC. and its' Wall Street News Alert brand. For current services performed for Sunwin International Neutraceuticals, Inc. (OTCBB: SUWN), China Direct Industries, Inc. ("China Direct Industries"), Dragon Capital Group Corp, China America Holdings and China Armco Metals, Inc., the company has been compensated a total of Fifty Thousand Dollars by China Direct Investments Inc., a Florida corporation, and a wholly owned subsidiary of China Direct. The company does not hold any shares of the stock. Because the company received compensation for its services, there is an inherent conflict of interest in the company statements and opinions and such statements and opinions cannot be considered independent.

The information contained in this press release is for informational purposes only, and not to be construed as an offer to sell or solicitation of an offer to buy any security. The company makes no representation or warranty relating to the validity of the facts presented nor does the company represent or warrant that all material facts necessary to make an investment decision are presented above. Stock Market Alerts LLC is an advertising company and therefore, this release should be viewed for informational purposes only.

The company relies exclusively on information gathered on the public company, such as public filings, press releases and its web sites. Investors should use the advertising information contained in this release as a starting point for conducting additional research on the public company in order to allow the investor to form his or her own opinion regarding the public company. Factual statements contained in this publication are made as of the date stated and they are subject to change without notice. The company is not a registered investment adviser, broker or a dealer.

Investing in the public company that this release is providing service for should be reviewed as speculative and a high-risk and may result in the loss of some or all of any investment.

This release may contain statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements.